The esterase B from Sphingobium sp. SM42 has the new de-arenethiolase activity against cephalosporin antibiotics. Sungkeeree P, Toewiwat N, Whangsuk W, Ploypradith P, Mongkolsuk S, Loprasert S. Biochem Biophys Res Commun. 2018 Nov 17;506(1):231-236. doi: 10.1016/j.bbrc.2018.10.078. Epub 2018 Oct 19.

28 Dec 2018
0
0

The esterase B from Sphingobium sp. SM42 has the new de-arenethiolase activity against cephalosporin antibiotics.
Sungkeeree P, Toewiwat N, Whangsuk W, Ploypradith P, Mongkolsuk S, Loprasert S.
Biochem Biophys Res Commun. 2018 Nov 17;506(1):231-236. doi: 10.1016/j.bbrc.2018.10.078. Epub 2018 Oct 19.

Tags

Share this

Related Posts

Potential health effects of exposure to carcinogenic compounds in incense smoke in temple workers. Navasumrit P, Arayasiri M, Hiang OM, Leechawengwongs M, Promvijit J, Choonvisase S, Chantchaemsai S, Nakngam N, Mahidol C, Ruchirawat M Chem Biol Interact173p19-31(2008 May 9)
28 Dec 2007
0

Potential health effects of exposure to carcinogenic compounds in incense smoke in temple workers. Navasumrit P, Arayasiri M, Hiang OM, Leechawengwongs M, Promvijit J, Choonvisase S, Chantchaemsai S, Nakngam N, Mahidol C, Ruchirawat M Chem Biol Interact173p19-31(2008 May 9)

Potential health effects of exposure to carcinogenic compounds in incense smoke in temple workers. Navasumrit P, Arayasiri M, Hiang OM, Leechawengwongs M, Promvijit J, Choonvisase S, Chantchaemsai S, Nakngam N, Mahidol C, Ruchirawat M Chem Biol Interact173p19-31(2008 May 9)
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More